Bringing science to wellbeing
Five clinical studies provide evidence that PCC® may have the ability to boost the immune system of both adults and infants, and to reduce the duration and severity of respiratory tract infections.
PCC® is a probiotic that appears to be capable of boosting the mucosal immune system to reduce the severity and duration of respiratory infections in male athletes, healthy adults and infants. PCC® also appears capable of reducing the inflammatory symptoms of atopic dermatitis in infants and to boost the immune response to a vaccine in adults. PCC® can produce these immune effects at daily doses (1-2 billion CFU) well below those of many commercial probiotic products, many of which contain high numbers of non-specific and untested lactobacilli. This is likely due to PCC®’s demonstrated superior ability to resist the harsh environment of the stomach, ensuring it survives in high numbers on its passage through the digestive system.
From these clinical and scientific studies, it can be concluded that PCC® represents a potential powerful booster of the immune response and GI tract to provide a variety of positive health benefits.
As our understanding grows of the critical role of the gastrointestinal flora in human health, Bioxyne expects to be able to demonstrate health benefits of PCC® through its effects on the gut microbiome. This is the subject of Bioxyne’s current clinical trial.
Read a summary of the studies and their findings
Suite 506, Level 550 Clarence St
Sydney, NSW 2000, Australia
P: +61 2 9078 8180
ABN: 97 084 464 193
Which of the following group do you best fit?